Incoterms and payment terms for importing pharmaceuticals from India.

Most guides for importing medicine from India stop at the regulatory question: is the product registered, is the supplier real, is the GMP certificate valid. This one starts where that leaves off. Once due diligence is done and you are ready to transact, two commercial decisions govern the deal, and getting them aligned is what makes a cross-border pharmaceutical purchase safe rather than a gamble. The first is the Incoterm. The second is the payment instrument. They meet at a single document set.

The two decisions every pharma import comes down to.

Separate the two levers in your head before you negotiate, because they answer different questions. The Incoterm answers "who controls and pays for which leg of the journey, and at what point does the risk of loss become mine." The payment instrument answers "when, and against what, does my money actually leave." A buyer who fixes one and leaves the other vague has agreed only half a deal.

The bridge between them is paperwork. Under a C-term Incoterm and under a Letter of Credit, it is the same pile of documents, the invoice, the transport document, the quality and origin certificates, that triggers both the handover of the goods and the release of the money. Align the Incoterm, the payment instrument and the document list and the transaction runs cleanly. Leave them inconsistent and a container or a payment gets stuck. Everything below is in the buyer's voice, and it assumes you have already vetted the counterparty; if you have not, start with our guide to verifying an Indian pharmaceutical exporter.

Incoterms 2020 in plain terms: the eleven ICC rules.

Incoterms are published by the International Chamber of Commerce, and the current edition is Incoterms 2020. It contains eleven three-letter rules that split into two families. Seven work for any mode of transport, including air and containerised sea freight: EXW, FCA, CPT, CIP, DAP, DPU and DDP. Four apply to sea and inland-waterway transport only: FAS, FOB, CFR and CIF. The 2020 edition kept the total at eleven and renamed the old DAT rule to DPU (Delivered at Place Unloaded).

The single feature most buyers miss is that, for one group of terms, cost transfer and risk transfer happen at different points. Under the C-terms (CFR, CIF, CPT and CIP) the seller pays the carriage all the way to the named destination, yet the risk of loss passes to you much earlier, at origin, when the goods are handed over to the carrier or loaded on the vessel. These are "shipment" contracts, not "arrival" contracts. A buyer who reads "CIF Lagos" as "the seller carries the risk to Lagos" has misread the rule. The seller carries the cost to Lagos and the risk only to the Indian port.

Read along the spectrum from least to most seller responsibility: EXW puts almost everything on the buyer (collect the goods at the seller's premises); DDP puts almost everything on the seller (deliver cleared and duty-paid at your door). Everything else sits between those poles, and the right choice depends on the mode of transport and on how much of the journey you are equipped to control.

Which Incoterm fits which pharma shipment, and which fits you.

Start with the mode, because it eliminates half the options. Most temperature-sensitive pharma moves by air, and air freight can only use the any-mode terms: FCA, CPT, CIP or DAP. FOB, CFR and CIF are sea terms and are simply the wrong instrument for an air waybill, even though they are widely and incorrectly quoted for air shipments. For containerised sea freight, the ICC specifically encourages FCA, CPT and CIP over FOB, CFR and CIF, because a container is handed over at a terminal, not loaded by the seller over the ship's rail; using FOB for a container leaves a risk gap at the terminal that nobody clearly owns.

Then match the term to your own capability. A first-time importer without a freight forwarder at the Indian end is usually better served by a C-term (CIP for air or containers, CIF for genuine bulk sea cargo), because the seller arranges the main carriage and a baseline insurance. An experienced importer with its own forwarder and negotiated freight rates will often prefer FCA or FOB, taking control of the main carriage to manage cost and routing. Neither is universally right. The honest rule is: pick the term that matches who is actually better placed to arrange and pay for each leg.

FOB and FCA vs CIF and CIP, the debate decided for pharma.

This is the choice most pharma buyers actually agonise over, so here it is resolved. Under FOB and FCA you, the buyer, arrange and pay for the main carriage and your own insurance. That gives an experienced importer full control of routing, carrier and rates, but it means you must have a forwarder at origin in India and you carry the insurance decision yourself. Under CIF and CIP the seller arranges the carriage and a minimum insurance to the destination, which is convenient, but remember the C-term trap: the risk still passes to you at origin. You are insured from loading, but the loss exposure is yours from the moment the goods leave the Indian port or terminal.

For the formats pharma actually ships in, the practical rule is short. Containers and air freight should use the any-mode terms (FCA, CPT or CIP). Reserve FOB, CFR and CIF for genuine bulk or break-bulk sea cargo where the goods really are loaded over the ship's rail. If a counterparty quotes you FOB or CIF on an air shipment, treat it as a sign the terms have not been thought through, and ask for the correct any-mode equivalent.

Why DDP is usually the wrong term for regulated pharma.

DDP (Delivered Duty Paid) looks attractive to a buyer because the seller appears to handle everything, including import clearance, duty and destination VAT or GST. For regulated medicine it is usually the wrong choice, and the reason is legal, not commercial. DDP makes the seller the importer of record in your country. But for registered pharmaceuticals the importer of record must generally be a locally licensed entity, a licensed importer or the marketing-authorisation holder, with the legal right to import that product. A foreign Indian exporter typically cannot be the importer of record for a controlled medicine, and many markets bar foreign entities from performing import and tax formalities at all.

The ICC's own guidance says DDP should be used with great care and that where the local party must clear the goods, DAP is the right term, not DDP. So for any market with a registration or import-permit regime, which is to say almost every market a serious pharma importer operates in, DAP or a C-term is the sensible ceiling. The licensed local importer clears the goods, pays the duty and holds the permit, exactly as the regulator requires. If a supplier offers you DDP into a regulated market, that is a prompt to check who they think will legally be the importer of record, because it usually has to be you.

Insurance: the minimum cover is not cold-chain cover.

Insurance is where the Incoterm and the product collide. Under Incoterms 2020 the seller's insurance obligation differs by term. CIF defaults to Institute Cargo Clauses (C), a restricted, named-perils minimum. CIP was upgraded in the 2020 edition and now requires the higher Institute Cargo Clauses (A), broadly "all risks." In both cases the cover must be for a minimum of 110 percent of the contract value, and the Institute Cargo Clauses are the standard cargo-insurance wordings maintained by the London market underwriters.

Here is the trap for temperature-sensitive lines. Even Institute Cargo Clauses (A) does not automatically pay for spoilage caused by a temperature excursion or a refrigeration breakdown. So for cold-chain pharma the term's default insurance is never enough on its own. Whatever the Incoterm, you need an explicit all-risks policy with a specific cold-chain or temperature endorsement. Before you accept any C-term quote, ask to see the insurance certificate and confirm three things: that it names the right clauses, that it covers 110 percent of value, and that it carries a temperature endorsement for a sensitive consignment. Our note on cold-chain validation and the West Africa cold-chain field report cover what that protection looks like in practice.

Payment terms: from advance to open account, and where pharma sits.

Picture the payment instruments as a trust curve, with the risk shifting from one side to the other as you move along it. At one end, 100 percent advance (TT) puts all the risk on the buyer: you have paid, and nothing now compels the seller to ship. At the other end, open account puts all the risk on the seller: they have shipped, and nothing compels you to pay. In between sit the instruments that exist precisely to make a stranger bankable for both parties.

The Letter of Credit (documentary credit), governed by the ICC's UCP 600, is the balanced middle. The buyer's bank undertakes to pay the seller, but only against shipping documents that comply exactly with the credit. The seller gets a bank-backed promise of payment; the buyer pays only once shipment is evidenced by documents. An LC "at sight" pays on presentation of compliant documents; a "usance" or deferred LC gives the buyer an agreed credit period (commonly 30, 60 or 90 days), and usance LCs are widely used by Indian pharma exporters where the buyer needs time.

Between the LC and open account sit the documentary collections, governed by the ICC's URC 522. Under Documents against Payment (D/P) the bank releases the shipping documents, and therefore control of the goods, only when the buyer pays. Under Documents against Acceptance (D/A) the buyer gets the documents against a dated promise to pay (an accepted bill of exchange), so the seller carries the credit risk until it matures. The key difference from an LC: a collection carries no bank guarantee of payment. The bank only handles documents. It is cheaper than an LC and gives the seller less security.

So where does pharma actually sit? A new counterparty should avoid paying 100 percent in advance, and a careful seller should avoid shipping a stranger on open account. The common, sensible middle for pharmaceutical trade is a partial advance plus the balance against shipping documents or an LC at sight, with usance LCs where the buyer has earned a credit period. Treat these as negotiated norms, not fixed rules; the exact split is agreed deal by deal and tightens or loosens with the relationship.

The document set that releases the goods and the money.

This is where the two levers become one. Under a C-term Incoterm the transport document is what evidences the seller has met the handover obligation, and under a Letter of Credit the document set is what the bank pays against. It is the same pile in both cases: the commercial invoice, packing list, transport document (bill of lading for sea, air waybill for air), Certificate of Analysis, Certificate of Pharmaceutical Product, certificate of origin and insurance certificate. The exact list is set by the contract and, where there is one, by the Letter of Credit.

The non-negotiable rule under UCP 600 is that banks examine documents, not goods, and reject on discrepancies. If the LC asks for an air waybill and the term implies a bill of lading, or a name is spelled two ways across two documents, payment can be refused even though the goods are perfectly fine. So the Incoterm's transport document and the LC's document list must be made to match exactly, before the goods move. The same documentation discipline that clears a regulator clears a bank; our WHO-GMP and CDSCO documentation guide covers how that certificate chain is produced on the Indian side, and the GDP export checklist covers the shipping-quality records.

One light note on the India side, included so you understand why payment routes the way it does. An Indian exporter needs an Importer Exporter Code (IEC) to export at all, and export proceeds must be received through an Authorised Dealer (AD) bank, which evidences receipt with a Foreign Inward Remittance Certificate and reports it to the Reserve Bank of India. Invoicing is commonly in USD or EUR. That is why your payment, whether by TT or under an LC, must route through the specific AD bank named in the contract or the credit, and not to some other account. If a supplier asks you to pay a different account from the one on the documents, stop and verify.

FAQ

What are Incoterms and who publishes them?

Incoterms are standardised three-letter trade terms published by the International Chamber of Commerce (ICC). The current edition is Incoterms 2020, which defines eleven rules that allocate the costs, risks and responsibilities of moving goods between a seller and a buyer in international trade.

Under FOB and CIF, when does the risk pass to me as the buyer?

Under both FOB and CIF the risk passes to the buyer at the port of loading, when the goods are placed on board the vessel. Under CIF the seller also pays the freight and a minimum insurance to the destination port, but that does not change where risk transfers. You carry the risk of loss from the moment the goods are loaded in India.

What is the difference between FOB and FCA, and which should I use for container or air shipments?

FOB is a sea and inland-waterway term where risk passes when goods are loaded on board the ship. FCA is an any-mode term where risk passes when goods are handed to the carrier at the named place. The ICC recommends FCA, CPT or CIP over FOB for containerised cargo, because containers are handed over at a terminal rather than loaded over the ship's side. For air freight only any-mode terms such as FCA, CPT, CIP or DAP apply; FOB and CIF are not appropriate.

Why is DDP usually a bad idea for importing registered medicines?

DDP is the only Incoterm that makes the seller responsible for import clearance, duty and destination VAT or GST, which effectively requires the seller to act as importer of record. For regulated pharmaceuticals the importer of record must usually be a locally licensed entity, and many countries require the local importer to perform import clearance or bar foreign entities from doing so. In those markets the ICC's own guidance points to DAP rather than DDP, so DAP or a C-term is the sensible ceiling for a regulated-pharma import.

How much insurance does the seller have to buy under CIF and CIP?

Under Incoterms 2020 the seller must insure for a minimum of 110 percent of the contract value. CIF's default cover is Institute Cargo Clauses (C), a restricted named-perils minimum, while CIP now requires the higher Institute Cargo Clauses (A), broadly all-risks. For temperature-sensitive pharmaceuticals you should not rely on the default term cover; arrange an explicit all-risks policy with a cold-chain or temperature endorsement regardless of the Incoterm.

As a first-time buyer, should I pay 100 percent in advance?

No. With a new counterparty, full advance puts all the risk on you, because nothing legally compels the seller to ship after being paid. A Letter of Credit, governed by ICC UCP 600, protects both sides: the issuing bank pays the seller only against compliant shipping documents, and you pay only once shipment is evidenced. A common pharma structure is a partial advance plus the balance against shipping documents or an LC at sight.

What is the difference between a Letter of Credit and Documents against Payment (D/P)?

A Letter of Credit, governed by UCP 600, carries the issuing bank's undertaking to pay against compliant documents, so it gives the seller a bank-backed payment promise and gives the buyer a documentary trigger. A documentary collection such as D/P, governed by ICC URC 522, carries no bank guarantee; the bank only releases the shipping documents to the buyer once the buyer pays. D/P is cheaper than an LC but offers the seller less security, and D/A (Documents against Acceptance) gives the buyer the documents against a dated payment promise, leaving the seller exposed until it matures.

Which documents control payment, and how do they tie to the Incoterm?

The same document set governs both the Incoterm handover and any LC payment: commercial invoice, packing list, transport document (bill of lading for sea, air waybill for air), Certificate of Analysis, Certificate of Pharmaceutical Product, certificate of origin and insurance certificate. Under UCP 600 banks examine the documents, not the goods, and pay only if the documents comply exactly, so the transport document required by the Incoterm and the documents listed in the LC must match precisely or payment can be refused for discrepancies.